Cadrenal Therapeutics, Inc. CVKD
As ofNov 16, 2026, 1:52 PM EST
- YTD
- -78.76%
- 1 year
- -87.60%
- Market cap
- 4.52M
- EPS (ttm)
- -4.91
- Shares out
- 1.66M
- Forward P/E
- -3.02
- YTD return
- -78.76%
- 1-year return
- -87.60%
- 50-day average
- 14.77
- Volume
- 63.59K
- Avg volume
- 485.25K
- Open
- 1.49
- Previous close
- 1.51
- Day's range
- 1.45 – 1.57
- 52-week range
- 0.816 – 12.50
- Price target
- 35.67 (+2376.9%)
5D +0.38 (+35.51%)
Key statistics
- 200-day average
- 9.61
- Enterprise value
- 13.49M
- Price / book
- 4.61
- Free cash flow
- -3.67M
- Total cash
- 4.36M
- Total debt
- 2.23K
- Return on equity
- -125.15%
- Short % of float
- 6.80%
Fundamental scorecard
7 of 25 checks passed on CVKD’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.83 | -2.18 | -0.35 | -19.13% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | -2.25 | +16.79 | +88.18% |
| Aug 7, 2024 | Jun 1, 2024 | -19.04 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.05 | -1.50 | -0.45 | -42.86% |
| Mar 11, 2024 | Dec 1, 2023 | -1.35 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 18, 2023 | Noble Capital Markets | init | — | Outperform |
| Nov 20, 2023 | HC Wainwright & Co. | init | — | Buy |
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cadrenal.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CVKD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MURPHY JOHN RAYMOND | Director | Purchase | Oct 4, 2023 | 614,792 |
| PHAM QUANG X | Chief Executive Officer | Stock Gift | Apr 9, 2024 | 6,275,000 |
| SZOT MATTHEW K | Chief Financial Officer | Stock Award(Grant) | Jan 23, 2023 | 500,000 |
| WILSON GLYNN | Director | Conversion of Exercise of derivative security | Jan 23, 2023 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Royal Bank of Canada | 0.00% | 25 | 356 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 5 | 71 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.19% | 3,216 | 45.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.07% | 1,109 | 15.81K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 923 | 13.16K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 60 | 855 | Sep 29, 2024 |
